Ozette Technologies, Inc., a Seattle, WA-based technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, raised $26M in Series A funding.
The round was led by Madrona Ventures with participation from Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners and Duke University.
The company intends to use the funds to accelerate growth and to expand its capabilities across a multiomic platform, integrating single cell proteomics and transcriptomics.
Led by Dr. Ali Ansary, CEO and Co-founder, Ozette is a life sciences technology startup building a high-resolution, intelligent, single-cell immune monitoring platform and corpus of high-resolution data leveraging its novel AI technologies. The AI-powered analysis, rooted in research pioneered at the Fred Hutchinson Cancer Center and incubated at the Allen Institute for Artificial Intelligence (AI2), reveals high-resolution, reliable insights an order of magnitude faster than the gold standard manual analysis. Early partners include small to large biopharma developing therapies in oncology, autoimmune disorders and infectious disease. Founded in late 2020, Ozette was spun-out from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. A new state-of-the-art immunology lab in development will soon offer another asset and avenue for partners to leverage the company’s technology, further enabling vertically integrated, automated analysis for immune insights.
FinSMEs
31/07/2022